Improving Alzheimer's detection: New strategic collaboration between Lucent Diagnostics and Tempus AI

Lucent Diagnostics, a brand of Quanterix Corporation announced a collaboration with Tempus AI Inc. to broaden access to a novel blood-based biomarker panel designed to improve detection accuracy for Alzheimer’s disease.

Through the agreement, Tempus AI will build a Tempus Next care gap program for Alzheimer’s disease blood-based biomarker testing, with the LucentAD Complete multi-biomarker blood test becoming available for neurologists to order on the Tempus clinical ordering platform.

More than 7 million Americans are living with Alzheimer’s disease today, yet only a small fraction are evaluated for eligibility for approved treatments. The collaboration aims to narrow that gap by embedding clinical guideline-directed identification and blood-based biomarker testing options directly into clinical decision-making workflows used by neurologists.

Tempus Next is an AI-enabled care pathway intelligence platform that identifies care gaps and equips providers with actionable insights consistent with clinical guidelines at the point of care. While the Tempus Next Care Gap Program helps identify patients who may benefit from biomarker testing based on established clinical guidelines, clinicians have the option to order LucentAD Complete through existing EHR integrations.

Read Lucent's Businesswire announcement here